此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.

2026年11月16日 更新者:CSPC Megalith Biopharmaceutical Co.,Ltd.

An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.

This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.

研究概览

详细说明

The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.

Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.

研究类型

介入性

注册 (估计的)

368

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
  2. Age 18-75 (inclusive) years;
  3. Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
  4. Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
  5. Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
  6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
  7. Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
  8. Life expectancy ≥ 3 months;
  9. Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.

Exclusion Criteria:

  1. Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
  2. Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
  3. Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
  4. Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
  5. Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
  6. History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:SYS6043+PD-1/VEGF bispecific antibody

SYS6043: IV PD-1/VEGF bispecific antibody: IV

实验性的:SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.

SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV

实验性的:SYS6043 monotherapy

SYS6043: IV

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase I: Incidences of AEs
大体时间:From the signing of the informed consent form until 90 days after the last dose.
From the signing of the informed consent form until 90 days after the last dose.
Phase I: DLT
大体时间:21 days

Dose-limiting toxicity

21 days
Phase I: MTD/RP2D
大体时间:After phase I dose escalation stage. Approximately 4 months.

Maximum Tolerated Dose/ Recommended Phase II Dose

After phase I dose escalation stage. Approximately 4 months.
Phase II: ORR
大体时间:Up to 2 years

Objective response rate

Up to 2 years

次要结果测量

结果测量
措施说明
大体时间
Phase I: ORR
大体时间:Up to 2 years

Objective response rate

Up to 2 years
Phase I:DCR
大体时间:Up to 2 years

Disease control rate

Up to 2 years
Phase I:DOR
大体时间:Up to 2 years

Duration of response

Up to 2 years
Phase I: TTR
大体时间:Up to 2 years

Time to Response

Up to 2 years
Phase I: PFS
大体时间:Up to 2 years

Progression free survival

Up to 2 years
Phase I:OS
大体时间:Up to 3 years

Overall survival

Up to 3 years
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
大体时间:Up to 2 years
Up to 2 years
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
大体时间:Up to 2 years
Up to 2 years
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
大体时间:Up to 2 years
Up to 2 years
Phase II:DCR
大体时间:Up to 2 years

Disease control rate

Up to 2 years
Phase II:DOR
大体时间:Up to 2 years

Duration of response

Up to 2 years
Phase II: TTR
大体时间:Up to 2 years

Time to Response

Up to 2 years
Phase II: PFS
大体时间:Up to 2 years

Progression free survival

Up to 2 years
Phase II:OS
大体时间:Up to 3 years
Up to 3 years
Title: Phase II: Incidences of AEs
大体时间:From the signing of the informed consent form until 90 days after the last dose.

Overall survival

From the signing of the informed consent form until 90 days after the last dose.
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
大体时间:Up to 2 years
Up to 2 years
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
大体时间:Up to 2 years
Up to 2 years
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
大体时间:Up to 2 years
Up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月30日

初级完成 (估计的)

2028年12月30日

研究完成 (估计的)

2029年12月30日

研究注册日期

首次提交

2026年11月13日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • SYS6043-005

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅